Paglalarawan

The autoimmune diseases treatment market in China in terms of revenue is set to grow by US$ 11 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 27% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix.

Ang ulat ay nagbibigay ng napapanahong data ng laki ng merkado para sa panahon 2017-2020 at forecast na 2027 covering key market aspects like sales value for autoimmune diseases treatment. The China autoimmune diseases treatment market is segmented on the basis of product, type. Ayon sa produkto, it is categorized into biologics, and small molecule chemical drugs. The small molecule chemical drugs segment held the largest market share in 2020. Gayunpaman, the biologics segment is expected to witness the highest CAGR during the forecast period. Ayon sa uri, the autoimmune diseases treatment market is divided into immunoglobulin A Nephropathy (IgAN), multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE).

The report has profiled some of the key players of the market such as UCB S.A., AbbVie Inc., GlaxoSmithKline plc., Janssen Pharmaceutica NV, Novartis International AG, Pfizer Inc., Roche Holding AG, Rongchang Pharmacy Co. Ltd..

Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the autoimmune diseases treatment market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

Saklaw ng Ulat

Produkto: biologics, and small molecule chemical drugs
Uri ng: immunoglobulin A Nephropathy (IgAN), multiple sclerosis (MS), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD), rheumatoid arthritis (RA), Sjogren’s syndrome (SS), and systemic lupus erythematosus (SLE)
Mga Taon na Itinuturing: Ang ulat na ito ay sumasaklaw sa panahon 2017 sa 2027

Mga Pangunahing Benepisyo para sa mga Stakeholder

Get a comprehensive picture of the China autoimmune diseases treatment market
Pinpoint ang mga sektor ng paglago at mga trend para sa pamumuhunan
Understand what the future of the autoimmune diseases treatment market in China looks like
Kilalanin ang mapagkumpitensya na landscape at window ng pagkakataon

Talaan ng mga Nilalaman

1. Kahulugan ng Market
2. Metodolohiya ng Pananaliksik
3. Market Data & Outlook
3.1 Halaga ng Market
3.2 Pagtataya ng Halaga sa Market
4. Autoimmune Diseases Treatment Market by Product
4.1 Biologics
4.2 Small Molecule Chemical Drugs
5. Autoimmune Diseases Treatment Market by Type
5.1 Immunoglobulin A Nephropathy (IgAN)
5.2 Multiple Sclerosis (MS)
5.3 Myasthenia Gravis (MG)
5.4 Neuromyelitis Optica Spectrum Disorder (NMOSD)
5.5 Rheumatoid Arthritis (RA)
5.6 Sjogren’S Syndrome (SS)
5.7 Systemic Lupus Erythematosus (SLE)
6. Mga Profile ng Kumpanya
6.1 UCB S.A.
6.2 AbbVie Inc.
6.3 GlaxoSmithKline plc.
6.4 Janssen Pharmaceutica NV
6.5 Novartis International AG
6.6 Pfizer, Inc.
6.7 Roche Holding AG
6.8 Rongchang Pharmacy Co., Ltd.
7. Apendiks
7.1 Tungkol sa StrategyHelix
7.2 Pagtanggi